Anavex reports long-term Alzheimer's data for drug with history of scrutiny
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative and CNS disorders …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
